Vaccitech are delighted to welcome Dr Steve Chatfield following his appointment as a Non-Executive Director with the Company. Steve has worked for more than 35 years in the Biopharmaceutical Industry and the public sector developing and commercialising public health interventions such as vaccines and immunotherapies.

He has worked at CSO, CEO, CBO and Executive management and Board level in several leading UK and International Biopharmaceutical Companies for more than 20 years. He served as Chief Scientific Officer and Executive Vice President of Strategic Investments for Emergent BioSolutions and President and CEO for the UK operation. He previously served on the Board and Executive teams of Microscience Ltd, (CSO and Chief Development Officer) Medeva PLC and the Health Protection Agency where he was Director of the Centre for Emergency Preparedness and Response at Porton Down.

Steve is now focussed on helping companies to translate research into products and now serves as a non-executive Director for Vaccitech Ltd, Prokarium Ltd (Chairman) and the Cell and Gene Therapy Catapult as well as advising other companies as a consultant.

He began his career working in Vaccine research and development at the Wellcome Foundation. Steve is also recognised internationally as an opinion leader in the field of Biotechnology. His research efforts have focussed on developing novel vaccines and immunotherapies. He has published over a 100 papers in this field and is named as an inventor on 20 patents. He also serves on the Scientific Advisory Board for the Jenner Institute (Oxford University) and is a Board Advisor to Envisage LLC.